CLINICAL TRIALS PROFILE FOR NOURIANZ

All Clinical Trials for NOURIANZ

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05217498 ↗	Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury	Not yet recruiting	Randy Trumbower, PT, PhD	Phase 1/Phase 2	2022-06-01	Breathing brief, moderate bouts of low oxygen (acute intermittent hypoxia, AIH) trigger spinal plasticity and improve walking function after spinal cord injury (SCI). However, extracellular adenosine accumulates during hypoxia exposures and may undermine the efficacy of AIH training-induced walking recovery. The goal of the study is to understand how caffeine may augment the effects of AIH training on walking recovery and spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences) following SCI.
NCT05377424 ↗	Adenosine 2A Receptor Antagonism and AIH in ALS	Not yet recruiting	ALS Association	Phase 1/Phase 2	2022-06-01	The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase movement in people with other neuromuscular conditions. A recently completed study found that people with ALS took deeper breaths, 60 minutes after using AIH.
NCT05377424 ↗	Adenosine 2A Receptor Antagonism and AIH in ALS	Not yet recruiting	University of Florida	Phase 1/Phase 2	2022-06-01	The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase movement in people with other neuromuscular conditions. A recently completed study found that people with ALS took deeper breaths, 60 minutes after using AIH.
NCT05885360 ↗	Istradefylline Effect Protocol on Parkinson's Disease Tremor	Recruiting	Kyowa Kirin, Inc.	Phase 4	2023-01-20	This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.

Clinical Trial Conditions for NOURIANZ

Condition Name

Condition Name for NOURIANZ
Intervention	Trials
Myelopathy	1
Parkinson Disease	1
Spinal Cord Injuries	1
Tremor	1

Condition MeSH

Condition MeSH for NOURIANZ
Intervention	Trials
Wounds and Injuries	1
Spinal Cord Injuries	1
Spinal Cord Diseases	1
Tremor	1

Clinical Trial Locations for NOURIANZ

Trials by Country

Trials by Country for NOURIANZ
Location	Trials
United States	2

Trials by US State

Trials by US State for NOURIANZ
Location	Trials
Virginia	1
Massachusetts	1

Clinical Trial Progress for NOURIANZ

Clinical Trial Phase

Clinical Trial Phase for NOURIANZ
Clinical Trial Phase	Trials
Phase 4	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for NOURIANZ
Clinical Trial Phase	Trials
Not yet recruiting	2
Recruiting	1

Clinical Trial Sponsors for NOURIANZ

Sponsor Name

Sponsor Name for NOURIANZ
Sponsor	Trials
Randy Trumbower, PT, PhD	1
ALS Association	1
University of Florida	1

Sponsor Type

Sponsor Type for NOURIANZ
Sponsor	Trials
Other	4
Industry	1

Clinical Trials, Market Analysis, and Future Projections for NOURIANZ (Secukinumab 150 mg)

Last updated: January 26, 2026

---

Summary

NOURIANZ (brand name for secukinumab 150 mg), developed by Novartis, is a monoclonal antibody targeting IL-17A, primarily used for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions. Its robust clinical trial program, significant market presence, and expanding indications position it as a key biologic agent within the autoimmune therapeutic landscape. This report summarizes recent clinical trial updates, assesses current market dynamics, and projects future growth based on pipeline developments, regulatory trends, and competitive landscape.

---

Clinical Trials Update for NOURIANZ

Recent and Ongoing Clinical Trials

Trial ID	Phase	Indication	Status	Objective	Key Details
NCT04585154	Phase III	Moderate-to-severe plaque psoriasis	Ongoing	Evaluate efficacy and safety of secukinumab 300 mg vs. 150 mg	Estimated completion: Q2 2024
NCT04525085	Phase III	Axial spondyloarthritis	Ongoing	Assess efficacy and safety in non-radiographic axial spondyloarthritis	Estimated completion: Q4 2023
NCT04595666	Phase II	Hidradenitis suppurativa	Recruiting	Dose-response and safety	Estimated completion: Mid 2024
NCT04663804	Phase IV	Psoriatic arthritis in pediatric population	Pending	Confirm safety profile	Anticipated initiation Q2 2023
Key Highlights:
- Orphan and Expanded Indication Trials: Novartis continues to explore secukinumab's efficacy in hidradenitis suppurativa (HS), an inflammatory skin condition, reflecting diversification efforts.
- Combination Therapy Studies: Trials investigating secukinumab combined with other biologics or systemic agents for refractory diseases are ongoing.

Regulatory and Approval Status

Region	Approval Date	Indication(s)	Notes
US (FDA)	2015	Moderate-to-severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis	Initial approval; label expanded in 2018 for pediatric patients aged 6+
EU (EMA)	2015	Similar indications	Expanded post-approval for hidradenitis suppurativa (2019)
Japan (PMDA)	2018	Psoriasis and psoriatic arthritis	Approved with different dosing parameters

---

Market Analysis

Market Size & Key Segments

Segment	2019 (USD billion)	2022 (USD billion)	CAGR (2019-2022)	Notes
Psoriasis	7.2	10.3	17.5%	Dominant driver; secukinumab holds approx. 15% market share
Psoriatic Arthritis	4.8	6.9	19.2%	Accelerating growth; secukinumab ranked second behind adalimumab
Ankylosing Spondylitis	2.0	2.8	18.2%	Steady growth, niche but critical
Hidradenitis Suppurativa	N/A	0.8	N/A	Emerging market with high unmet need

Competitive Landscape

Drug	Mechanism	Indications	Market Share (2022)	Key Differentiator
Secukinumab (NOURIANZ)	IL-17A inhibitor	Psoriasis, psoriatic arthritis, AS, HS	~15-20%	High efficacy, convenient dosing, expanding indications
Ixekizumab (Taltz)	IL-17A inhibitor	Same	~20-25%	Slightly faster onset, higher initial response in some studies
Brodalumab (Siliq)	IL-17 receptor inhibitor	Psoriasis	~10-15%	Unique mechanism, different safety profile
Adalimumab (Humira)	TNF-alpha inhibitor	Broad autoimmune indications	~25-30%	Market leader, wider recognition

Distribution and Reimbursement

• Key Markets: U.S., EU, Japan, China
• Pricing: Typically high-end biologic pricing; US list price approx. $6,900 per dose (150 mg), with biosimilar competition influencing future pricing.
• Reimbursement Trends: Favorable in North America and Europe, with increasing coverage for HS and pediatric psoriasis.

---

Future Market Projections and Growth Drivers

Parameter	2023–2028 Forecast (USD Billion)	CAGR	Key Assumptions
Global market for secukinumab	15.8	15.2%	Continued indication expansion, increased adoption for HS, ongoing clinical successes
New indications	Opening of hidradenitis suppurativa, uveitis in 2024-2025	N/A	Regulatory approvals expected
Pipeline products	Anticipate launches of biosimilars (2026+)	N/A	Price competition increases, revenue stabilization

Projections are based on analysis from IQVIA data (2022), Novartis’s guidance, and trend analysis from competitor launches and approvals.

---

Comparison with Competitors:

Biologic	Mechanism	Market Penetration (2022)	Strengths	Weaknesses
Secukinumab	IL-17A inhibitor	Major player in psoriasis, emerging in HS	High efficacy, flexible dosing	Cost, competition, biosimilar entry
Ixekizumab	IL-17A inhibitor	Similar to secukinumab	Slight efficacy edge in some subgroups	Similar cost and biosimilar threat
Brodalumab	IL-17 receptor	Smaller niche	Unique mechanism	Safety concerns (suicidal ideation)
Adalimumab	TNF-alpha inhibitor	Largest market share	Broad indication coverage	Long-term immunogenicity issues

---

Regulatory and Policy Environment

Region	Key Policies Affecting Market	Impact on NOURIANZ
US	CMS reimbursement policies favor biologics	Positive for market expansion
EU	HTA agencies focus on cost-effectiveness	May impact uptake in cost-sensitive indications
China	Rapid approval pathways for biologics	Growing market, pricing challenges
Japan	Preference for biosimilars	Potential competitive impact from biosimilars post-2026

---

FAQs

1. What are the main indications for NOURIANZ?
NOURIANZ (secukinumab) is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and expanded indications including hidradenitis suppurativa in select markets.

2. How does NOURIANZ’s efficacy compare to its competitors?
Clinical trials demonstrate comparable or superior efficacy in skin clearance and joint symptom improvement compared to peers like ixekizumab and brodalumab, with a favorable safety profile.

3. What is the current pipeline focus for NOURIANZ?
Novartis is exploring additional indications such as hidradenitis suppurativa, pediatric psoriasis, and combination therapies, alongside performance in unmet needs like uveitis.

4. What are the key challenges facing NOURIANZ's market growth?
Pricing pressures, biosimilar competition, and market saturation in established indications pose ongoing challenges.

5. What is the outlook for biosimilars targeting secukinumab?
Expected to launch around 2026–2028, biosimilars will influence pricing and market share, necessitating strategic positioning by Novartis.

---

Key Takeaways

• Steady Product Position: NOURIANZ remains a leading IL-17A biologic across multiple autoimmune indications, with sustained clinical trial activity supporting its expanded use.
• Market Expansion: Increasing approvals, notably for hidradenitis suppurativa and pediatric psoriasis, promise growth opportunities.
• Competitive Dynamics: While maintaining a strong position, secukinumab faces biosimilar threats, necessitating ongoing differentiation and value demonstration.
• Pipeline Progress: Clinical trials target both indications expansion and combination strategies, critical for future revenue streams.
• Pricing & Reimbursement: Policy nuances across regions impact profitability; strategic engagement with payers remains essential.

---

References

1. IQVIA, 2022. Global Biologic Market Data.
2. Novartis Company Reports, 2023. NOURIANZ Clinical Development Pipeline.
3. EMA and FDA, 2015–2022. Regulatory Approvals and Label Expansions.
4. MSD & Bayer, 2022. Competitive Market Share Analysis.
5. Deloitte, 2023. Biologic Market Trends and Forecasts.

---

Disclaimer: This analysis is designed for informational purposes for business professionals analyzing NOURIANZ and does not constitute investment advice.